Literature DB >> 18032010

Cell cycle markers in clinical oncology.

Gareth H Williams1, Kai Stoeber.   

Abstract

Analysis of complex and redundant pathways that control proliferation, differentiation, apoptosis and DNA damage response by global genome wide analysis is an intensive area of investigation aimed at identifying unique molecular signatures of prognostic significance in cancer. An alternative approach is to focus on the cell cycle machinery, which acts as an integration point for information transduced through upstream signalling pathways. Analysis of the DNA replication licensing pathway and the mitotic regulatory machinery in tumour biopsy material is now leading to the identification of novel biomarkers that are being exploited in cancer detection and prognostic assessment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18032010     DOI: 10.1016/j.ceb.2007.10.005

Source DB:  PubMed          Journal:  Curr Opin Cell Biol        ISSN: 0955-0674            Impact factor:   8.382


  25 in total

1.  Reducing MCM levels in human primary T cells during the G(0)-->G(1) transition causes genomic instability during the first cell cycle.

Authors:  S J Orr; T Gaymes; D Ladon; C Chronis; B Czepulkowski; R Wang; G J Mufti; E M Marcotte; N S B Thomas
Journal:  Oncogene       Date:  2010-05-03       Impact factor: 9.867

Review 2.  DNA replication licensing control and rereplication prevention.

Authors:  Chonghua Li; Jianping Jin
Journal:  Protein Cell       Date:  2010-02-23       Impact factor: 14.870

3.  Activation of postnatal neural stem cells requires nuclear receptor TLX.

Authors:  Wenze Niu; Yuhua Zou; Chengcheng Shen; Chun-Li Zhang
Journal:  J Neurosci       Date:  2011-09-28       Impact factor: 6.167

4.  Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers.

Authors:  Sara Rodriguez-Acebes; Ian Proctor; Marco Loddo; Alex Wollenschlaeger; Mohammed Rashid; Mary Falzon; A Toby Prevost; Richard Sainsbury; Kai Stoeber; Gareth H Williams
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

5.  Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.

Authors:  Enrique Colado; Teresa Paíno; Patricia Maiso; Enrique M Ocio; Xi Chen; Stela Alvarez-Fernández; Norma C Gutiérrez; Jesús Martín-Sánchez; Juan Flores-Montero; Laura San Segundo; Mercedes Garayoa; Diego Fernández-Lázaro; Maria-Belen Vidriales; Carlos M Galmarini; Pablo Avilés; Carmen Cuevas; Atanasio Pandiella; Jesús F San-Miguel
Journal:  Haematologica       Date:  2011-02-17       Impact factor: 9.941

6.  Transient association of MCM complex proteins with the nuclear matrix during initiation of mammalian DNA replication.

Authors:  Emma L Hesketh; John R P Knight; Rosemary H C Wilson; James P J Chong; Dawn Coverley
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

7.  Radiation-induced cellular senescence results from a slippage of long-term G2 arrested cells into G1 phase.

Authors:  Caiyong Ye; Xurui Zhang; Jianghua Wan; Lei Chang; Wentao Hu; Zhitong Bing; Sheng Zhang; Junhong Li; Jinpeng He; Jufang Wang; Guangming Zhou
Journal:  Cell Cycle       Date:  2013-04-09       Impact factor: 4.534

8.  DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma.

Authors:  Oliver J Kayes; Marco Loddo; Nimish Patel; Pranav Patel; Suks Minhas; Gareth Ambler; Alex Freeman; Alex Wollenschlaeger; David J Ralph; Kai Stoeber; Gareth H Williams
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

9.  In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.

Authors:  Mariam M AlHilli; Marc A Becker; S John Weroha; Karen S Flatten; Rachel M Hurley; Maria I Harrell; Ann L Oberg; Matt J Maurer; Kieran M Hawthorne; Xiaonan Hou; Sean C Harrington; Sarah McKinstry; X Wei Meng; Keith M Wilcoxen; Kimberly R Kalli; Elizabeth M Swisher; Scott H Kaufmann; Paul Haluska
Journal:  Gynecol Oncol       Date:  2016-09-08       Impact factor: 5.482

Review 10.  DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer.

Authors:  Jason M D'Antonio; Donald J Vander Griend; John T Isaacs
Journal:  Endocr Relat Cancer       Date:  2009-02-24       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.